Additional diagnostic capabilities in the practice of a PAP-test using liquid-based cytology

Cover Page

Cite item

Full Text

Abstract

The role of oncogenic strains of human papillomavirus in the development of cervical cancer is currently not in doubt. In cervical cancer screening, a co-testing strategy is used, in which cytology and HPV testing are performed. When performing a cytological examination by liquid-based cytology, it is possible to conduct additional diagnostic studies that can be used to more effectively sort patients in order to optimize the volume of diagnostic and therapeutic measures. The article highlights the possibilities of diagnostic tests based on the assessment of microRNA and mRNA expression, as well as tests based on the analysis of DNA methylation from the cytological material. The introduction of new molecular genetic predictors of the cervical cancer development into clinical practice can increase the effectiveness of currently used screening programs.

About the authors

Artem K. Aksamentov

Federal Research and Clinical Center of Specialized Medical Care and Medical Technologies FMBA of Russia

Author for correspondence.
Email: temaaxe@rambler.ru
ORCID iD: 0000-0002-7980-2537
SPIN-code: 7861-6556

MD

Russian Federation, 28 Orekhovy boulevard, Moscow, 115682

Nadezhda V. Melnikova

Federal Research and Clinical Center of Specialized Medical Care and Medical Technologies FMBA of Russia; Russian Scientific Center of Roentgenoradiology

Email: n_melnikova@list.ru
ORCID iD: 0000-0003-1193-352X
SPIN-code: 5050-8605

Cand. Sci. (Med.)

Russian Federation, 28 Orekhovy boulevard, Moscow, 115682; Moscow

Nadezhda A. Kolyshkina

Federal Research and Clinical Center of Specialized Medical Care and Medical Technologies FMBA of Russia

Email: baklab_83@mail.ru
ORCID iD: 0000-0003-4486-5412

MD

Russian Federation, 28 Orekhovy boulevard, Moscow, 115682

Olga N. Kucherova

City Clinical Hospital named after V.V. Vinogradov of the Department of Health of the city of Moscow

Email: ola-kucherova@mail.ru
ORCID iD: 0000-0003-3773-9629

Cand. Sci. (Med)

Russian Federation, Moscow

Vladimir P. Baklaushev

Federal Research and Clinical Center of Specialized Medical Care and Medical Technologies FMBA of Russia

Email: baklaushev.vp@fnkc-fmba.ru
ORCID iD: 0000-0003-1039-4245
SPIN-code: 3968-2971

Dr. Sci. (Med.)

Russian Federation, 28 Orekhovy boulevard, Moscow, 115682

References

  1. Wild CP, Weiderpass E, Stewart BW. World Cancer Report: Cancer Research for Cancer Prevention. Lyon, France: International Agency for Research on Cancer, 2020. Avalable from: https://www.iarc.who.int/featured-news/new-world-cancer-report/
  2. Злокачественные новообразования в России в 2019 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. Москва: МНИОИ им. П.А. Герцена — филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2020. 252 с. [Malignant neoplasms in Russia in 2019 (morbidity and mortality). Ed. by A.D. Kaprin, V.V. Starinsky, A.O. Shakhzadova. Moscow: P.A. Herzen Moscow State Medical Research Institute-branch of the Federal State Budgetary Institution «NMIC of Radiology» of the Ministry of Health of Russia; 2020. 252 p. (In Russ).]
  3. Клинические рекомендации. Цервикальная интраэпителиальная неоплазия, эрозия и эктропион шейки матки. Общероссийская общественная организация «Российское общество специалистов по профилактике и лечению опухолей репродуктивной системы», Российское общество акушеров-гинекологов, 2020. [Clinical recommendations. Cervical intraepithelial neoplasia, erosion and ectropion of the cervix. All-Russian public organization «Russian Society of Specialists in the Prevention and Treatment of Tumors of the Reproductive System», Russian Society of Obstetricians and Gynecologists; 2020. (In Russ).] Режим доступа: https://sudact.ru/law/klinicheskie-rekomendatsii-tservikalnaia-intraepitelialnaia-neoplaziia-eroziia-i/klinicheskie-rekomendatsii/. Дата обращения: 12.02.2021.
  4. Rozemeijer K, Penning C, Siebers AG, et al. Comparing SurePath, ThinPrep, and conventional cytology as primary test method: SurePath is associated with increased CIN II + detection rates. Cancer Causes Control. 2016;27(1):15–25. doi: 10.1007/s10552-015-0678-1
  5. De Oliveira AC, Domingues MF, Neufeld PM, et al. Comparison between Conventional Cytology and Liquid-Based Cytology in the Tertiary Brazilian Navy Hospital in Rio de Janeiro. Acta Cytol. 2020;64(6):539–546. doi: 10.1159/000508018
  6. Taylor S, Kuhn L, Dupree W, et al. Direct comparison of liquid-based and conventional cytology in a South African screening trial. Int J Cancer. 2006;118(4):957–962. doi: 10.1002/ijc.21434
  7. Comprehensive Cytopathology. 3th Edition. Bibbo M.D., Wilbur, Elsevier; 2008.
  8. Hoda RS, VandenBussche C, Hoda SA. Liquid-Based Specimen Collection, Preparation, and Morphology. In: Hoda RS, VandenBussche C, Hoda SA, ed. Diagnostic Liquid-Based Cytology. Berlin, Heidelberg: Springer; 2017. Р. 1–12.
  9. Whitlock EP, Vesco KK, Eder M, et al. Liquid-based cytology and human papillomavirus testing to screen for cervical cancer: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2011;155(10):687–697. doi: 10.7326/0003-4819-155-10-201111150-00376
  10. Ho GY, et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998;338(7):423–428. doi: 10.1056/NEJM199802123380703
  11. Koliopoulos G, et al. Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta-analysis of non-randomized studies. Gynecol Oncol. 2007;104(1):232–246. doi: 10.1016/j.ygyno.2006.08.053
  12. Mayrand MH, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007;357(16):1579–1588. doi: 10.1056/NEJMoa071430
  13. Altobelli E, et al. HPV-vaccination and cancer cervical screening in 53 WHO European Countries: An update on prevention programs according to income level. Cancer Med. 2019;8(5):2524–2534. doi: 10.1002/cam4.2048
  14. Leeman A, et al. Reliable identification of women with CIN3+ using hrHPV genotyping and methylation markers in a cytology-screened referral population. Int J Cancer. 2019;144(1):160–168. doi: 10.1002/ijc.31787
  15. Schmitz M, et al. Performance of a methylation specific real-time PCR assay as a triage test for HPV-positive women. Clin Epigenetics. 2017;9. doi: 10.1186/s13148-017-0419-2
  16. Arbyn M, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine. 2012;30(Suppl 5):F88–99. doi: 10.1016/j.vaccine.2012.06.095
  17. Bergeron C, et al. Prospective evaluation of p16/Ki-67 dual-stained cytology for managing women with abnormal Papanicolaou cytology: PALMS study results. Cancer Cytopathol. 2015;123(6):373–381. doi: 10.1002/cncy.21542
  18. Lannér L, Lindström AK. Incidence of HPV and HPV related dysplasia in elderly women in Sweden. PloS One. 2020;15(3):e0229758. doi: 10.1371/journal.pone.0229758
  19. Luttmer R, et al. p16/Ki-67 dual-stained cytology for detecting cervical (pre)cancer in a HPV-positive gynecologic outpatient population. Mod Pathol Off. J. U. S. Can Acad Pathol Inc. 2016;29(8):870–878. doi: 10.1038/modpathol.2016.80
  20. Wentzensen N. et al. p16/Ki-67 Dual Stain Cytology for Detection of Cervical Precancer in HPV-Positive Women. JNCI J. Natl. Cancer Inst. 2015;107(12. doi: 10.1093/jnci/djv257
  21. Wentzensen N, et al. Clinical Evaluation of Human Papillomavirus Screening With p16/Ki-67 Dual Stain Triage in a Large Organized Cervical Cancer Screening Program. JAMA Intern Med. 2019;179(7):881–888. doi: 10.1001/jamainternmed.2019.0306
  22. Carozzi F, et al. Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial. Lancet Oncol. 2008;9(10):937–945. doi: 10.1016/S1470-2045(08)70208-0
  23. Ovestad IT, et al. Clinical value of fully automated p16/Ki-67 dual staining in the triage of HPV-positive women in the Norwegian Cervical Cancer Screening Program. Cancer Cytopathol. 2017;125(4):283–291. doi: 10.1002/cncy.21807
  24. Collaço LM, Zardo L. CHAPTER 3 – Cytologic Screening Programs. Comprehensive Cytopathology (Third Edition). Ed. Bibbo M., Wilbur D. Edinburgh: W.B. Saunders; 2008. Р. 47–57.
  25. Jamison J, Wilson RT, Carson J. The evaluation of human papillomavirus genotyping in cervical liquid-based cytology specimens; using the Roche Linear Array HPV genotyping assay. Cytopathol Off J Br Soc Clin Cytol. 2009;20(4):242–248. doi: 10.1111/j.1365-2303.2009.00643.x
  26. Sahebali S, et al. Immunocytochemistry in liquid-based cervical cytology: analysis of clinical use following a cross-sectional study. Int J Cancer. 2006;118(5):1254–1260. doi: 10.1002/ijc.21489
  27. Bubendorf L. Multiprobe fluorescence in situ hybridization (UroVysion) for the detection of urothelial carcinoma – FISHing for the right catch. Acta Cytol. 2011;55(2):113–119. doi: 10.1159/000323652
  28. Macfarlane LA, Murphy PR. MicroRNA: Biogenesis, Function and Role in Cancer. Curr Genomics. 2010;11(7):537–561. doi: 10.2174/138920210793175895
  29. Iorio MV, Croce CM. Causes and consequences of microRNA dysregulation. Cancer J Sudbury Mass. 2012;18(3):215–222. doi: 10.1097/PPO.0b013e318250c001
  30. Ribeiro J, et al. miR-34a and miR-125b Expression in HPV Infection and Cervical Cancer Development. BioMed Res. Int. 2015;(2015):304584. doi: 10.1155/2015/304584
  31. Malta M, et al. Let-7c is a Candidate Biomarker for Cervical Intraepithelial Lesions: A Pilot Study. Mol Diagn Ther. 2015;19(3):191–196. doi: 10.1007/s40291-015-0145-4
  32. Tian Q, et al. MicroRNA detection in cervical exfoliated cells as a triage for human papillomavirus-positive women. J Natl Cancer Inst. 2014;106:9. doi: 10.1093/jnci/dju241
  33. Lu J, et al. Regulation of Canonical Oncogenic Signaling Pathways in Cancer via DNA Methylation. Cancers. 2020;12:11. doi: 10.3390/cancers12113199
  34. Tirado-Magallanes R, et al. Whole genome DNA methylation: beyond genes silencing. Oncotarget. 2016;8(3):5629–5637. doi: 10.18632/oncotarget.13562
  35. Mirabello L, et al. Elevated methylation of HPV16 DNA is associated with the development of high grade cervical intraepithelial neoplasia. Int J Cancer. 2013;132(6):1412–1422. doi: 10.1002/ijc.27750
  36. Piyathilake CJ, et al. A higher degree of methylation of the HPV 16 E6 gene is associated with a lower likelihood of being diagnosed with cervical intraepithelial neoplasia. Cancer. 2011;117(5):957–963. doi: 10.1002/cncr.25511
  37. Kottaridi C, et al. Quantitative Measurement of L1 Human Papillomavirus Type 16 Methylation for the Prediction of Preinvasive and Invasive Cervical Disease. J Infect Dis. 2017;215(5):764–771. doi: 10.1093/infdis/jiw645
  38. Lorincz AT. Virtues and Weaknesses of DNA Methylation as a Test for Cervical Cancer Prevention. Acta Cytol. 2016;60(6):501–512. doi: 10.1159/000450595
  39. Bonde J, et al. Methylation markers FAM19A4 and MIR124 -2 as triage strategy for primary human papillomavirus screen positive women: A large European multicenter study. Int J Cancer. 2021;148(2):396–405. doi: 10.1002/ijc.33320
  40. Leeman A, et al. Expression of p16 and HPV E4 on biopsy samples and methylation of FAM19A4 and miR124-2 on cervical cytology samples in the classification of cervical squamous intraepithelial lesions. Cancer Med. 2020;9(7):2454–2461. doi: 10.1002/cam4.2855
  41. Dippmann C, et al. Triage of hrHPV-positive women: comparison of two commercial methylation-specific PCR assays. Clin Epigenetics. 2020;12. doi: 10.1186/s13148-020-00963-w
  42. De Vuyst H, et al. Methylation Levels of CADM1, MAL, and MIR124-2 in Cervical Scrapes for Triage of HIV-Infected, High-Risk HPV-Positive Women in Kenya. J Acquir Immune Defic Syndr. 2015;70(3):311–318. doi: 10.1097/QAI.0000000000000744
  43. Kong L, et al. DNA methylation for cervical cancer screening: a training set in China. Clin Epigenetics. 2020;12. doi: 10.1186/s13148-020-00885-7
  44. van Leeuwen RW, et al. DNA methylation markers as a triage test for identification of cervical lesions in a high risk human papillomavirus positive screening cohort. Int J Cancer. 2019;144(4):746–754. doi: 10.1002/ijc.31897
  45. Kim MK, et al. DNA methylation in human papillomavirus-infected cervical cells is elevated in high-grade squamous intraepithelial lesions and cancer. J Gynecol Oncol. 2016;27:2. doi: 10.3802/jgo.2016.27.e14
  46. Tsoumpou I, et al. p16(INK4a) immunostaining in cytological and histological specimens from the uterine cervix: a systematic review and meta-analysis. Cancer Treat Rev. 2009;35(3):210–220. doi: 10.1016/j.ctrv.2008.10.005
  47. Del Pino M, et al. mRNA biomarker detection in liquid-based cytology: a new approach in the prevention of cervical cancer. Mod Pathol Off J. U. S. Can Acad Pathol Inc. 2015;28(2):312–320. doi: 10.1038/modpathol.2014.106
  48. Мельникова Н.В., Антонова И.Б., Бабаева Н.А., и др. Результаты выявления, типирования и количественного определения вируса папилломы человека методом ПЦР в практике жидкостной цитологии у женщин в постменопаузе // Вестник Российского научного центра рентгенрадиологии. 2020. Т. 20, № 4. С. 134–151. [Melnikova NV, Antonova IB, Babaeva NA, et al. Results of detection, typing and quantification of human papillomavirus by PCR in thepractice of liquid cytology in postmenopausal women. Bulletin of the Russian Scientific Center of Roentgenoradiology. 2020;20(4): 134–151. (In Russ).]
  49. Wang HY, et al. Use of hTERT and HPV E6/E7 mRNA RT-qPCR TaqMan assays in combination for diagnosing high-grade cervical lesions and malignant tumors. Am J Clin Pathol. 2015;143(3):344–351. doi: 10.1309/AJCPF2XGZ2XIQYQX
  50. Мельникова Н.В., Боженко В.К., Антонова И.Б., и др. Цервикальные интраэпителиальные неоплазии: анализ профиля МРНК в практике жидкостной цитологии // Акушерство и гинекология. 2017. № 4. 95-100. [Melnikova NV, Bozhenko VK, Antonova IB, et al. Cervical intraepithelial neoplasia: analysis of mrna profile in the practice of liquid-based cytology. Obstetrics and gynegology. 2017;(4). 95-100. (In Russ).] doi: 10.18565/AIG.2017.4.95-100

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2021 Aksamentov A.K., Melnikova N.V., Kolyshkina N.A., Kucherova O.N., Baklaushev V.P.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies